Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...
Philadelphia, February 20, 2025 – Endomyocardial biopsy (EMB) is a valuable method for diagnosing a range of cardiac conditions, but there is a risk of complication due to its invasive nature.
MedPage Today on MSN
MicroRNA tests eyed for flagging heart transplant rejection
Panels designed to identify acute cellular rejection, antibody-mediated rejection without ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Endomyocardial biopsies (EMBs) may be losing favor as ...
Endomyocardial biopsy (EMB) is a valuable method for diagnosing a range of cardiac conditions, but there is a risk of complication due to its invasive nature. Researchers have now found a way to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results